Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Homology Medicines raises $83.5mm in Series B round

Executive Summary

Homology Medicines Inc. (gene editing and gene therapy technologies) raised $83.5mm in its Series B financing round led by Deerfield Management. New investors Fidelity Management and Research, HBM Healthcare Investments, Maverick Ventures, Novartis AG, Rock Springs Capital, Vida Ventures, Vivo Capital (also adds a board seat), and Alexandria Venture Investments joined repeat backers 5AM Ventures, ARCH Venture Partners, and Temasek. The company previously raised $44mm in a Series A round back in May 2016. Homology expects to use the proceeds to advance its lead candidate (currently in preclinical IND-enabling studies for an inborn error of metabolism disease) and to support continued work on its AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) technology for rare genetic diseases.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies